<p>資本集團私人客户服務公司在最近向證券交易委員會的披露中表示，在第四季度減少了對安進公司（NASDAQ:AMGN - 免費報告）27.7% 的持股。該基金在此期間出售了 25,906 股後，持有 67,479 股這家醫療研究公司的股票。資本集團私人客户服務公司在安進的持股在最近的報告期末價值為 17,588,000 美元。</p>
<ul>
<li>MarketBeat 週報 – 12/2 - 12/6</li>
</ul>
<p>其他機構投資者和對沖基金最近也對該公司的持股進行了調整。Talbot Financial LLC 在第四季度將其在安進的持股增加了 5.6%。Talbot Financial LLC 目前持有 42,791 股這家醫療研究公司的股票，價值為 11,153,000 美元，此前在上個季度又增持了 2,274 股。資產顧問投資管理公司在第三季度將其在安進的持股提高了 9.0%。資產顧問投資管理公司目前持有 35,934 股這家醫療研究公司的股票，價值為 11,578,000 美元，此前在此期間又增持了 2,954 股。Ascent Wealth Partners LLC 在第四季度將其在安進的持股增加了 0.7%。Ascent Wealth Partners LLC 目前持有 9,024 股這家醫療研究公司的股票，價值為 2,352,000 美元，此前在上個季度又購買了 64 股。Principal Financial Group Inc.在第三季度將其在安進的持股提高了 6.0%。Principal Financial Group Inc.目前持有 635,172 股這家醫療研究公司的股票，價值為 204,659,000 美元，此前在此期間又購買了 35,785 股。最後，ICICI Prudential Asset Management Co Ltd 在第四季度將其在安進的持股增加了 242.2%。ICICI Prudential Asset Management Co Ltd 目前持有 23,999 股這家醫療研究公司的股票，價值為 6,255,000 美元，此前在上個季度又購買了 16,985 股。機構投資者持有該公司 76.50% 的股票。</p>
<h2>安進價格表現</h2>
<p>安進的股票在週五開盤價為 277.29 美元。該公司的債務與股本比率為 9.62，流動比率為 1.26，速動比率為 0.95。該股票的 50 日簡單移動平均線為 303.04 美元，200 日簡單移動平均線為 294.22 美元。該公司的市值為 1490.9 億美元，市盈率為 36.73，PEG 比率為 2.63，貝塔值為 0.59。安進的 1 年最低價為 253.30 美元，1 年最高價為 346.85 美元。</p>
<ul>
<li>安進股票因減肥藥數據下跌：反應過度還是合理？</li>
</ul>
<p>安進（NASDAQ:AMGN - 獲取免費報告）最近在 2 月 4 日（星期二）發佈了其財報。這家醫療研究公司報告的季度每股收益為 5.31 美元，超出市場共識預期的 5.04 美元，超出幅度為 0.27 美元。安進的淨利潤率為 12.24%，股本回報率為 176.32%。分析師預測，安進在當前年度的每股收益將達到 20.62 美元。</p>
<h2>安進宣佈分紅</h2>
<p>該公司最近還宣佈了一項季度分紅，將於 6 月 6 日（星期五）支付。5 月 16 日（星期五）的登記投資者將獲得每股 2.38 美元的分紅。該分紅的除息日為 5 月 16 日（星期五）。這相當於年化分紅為 9.52 美元，收益率為 3.43%。安進的分紅支付比率目前為 126.09%。</p>
<h2>安進的內部買賣</h2>
<ul>
<li>2 只准備在 2025 年飆升的仿製藥股票</li>
</ul>
<p>在其他安進新聞中，高級副總裁 Nancy A. Grygiel 在 2 月 5 日（星期三）出售了 1,589 股公司的股票。該股票以 304.47 美元的平均價格出售，總交易額為 483,802.83 美元。交易後，這位高級副總裁現在直接持有 7,210 股公司的股票，價值約為 2,195,228.70 美元。此次交易使其持股減少了 18.06%。該出售在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。此外，執行副總裁 David M. Reese 在 2 月 21 日（星期五）出售了 25,225 股公司的股票。該股票以 304.44 美元的平均價格出售，總交易額為 7,679,499.00 美元。交易完成後，這位執行副總裁現在直接持有 36,922 股公司的股票，價值約為 11,240,533.68 美元。這代表其持股減少了 40.59%。該出售的披露信息可以在此找到。內部人士在過去 90 天內出售了 69,341 股公司股票，價值為 20,644,335 美元。內部人士持有公司 0.69% 的股票。</p>
<h2>分析師評級變動</h2>
<p>安進最近成為幾份研究報告的主題。Piper Sandler Companies 在 1 月 2 日（星期四）的研究報告中重申了對安進股票的 “增持” 評級，並給出了 310.00 美元的目標價。花旗集團在 2 月 5 日（星期三）的報告中重申了對安進股票的 “中性” 評級。美國銀行在 3 月 5 日（星期三）將安進股票的目標價從 275.00 美元上調至 294.00 美元，並給予該股票 “跑輸大盤” 的評級。Piper Sandler 在 2 月 10 日（星期一）將安進股票的目標價從 310.00 美元上調至 329.00 美元，並給予該公司 “增持” 評級。最後，富國銀行在 2 月 5 日（星期三）的研究報告中重申了對安進股票的 “持平” 評級。兩位投資分析師對該股票給予了賣出評級，九位給予了持有評級，十二位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 314.91 美元。</p>
<p><strong>查看我們關於安進的最新報告</strong></p>
<h2>關於安進</h2>
<p>（免費報告）</p>
<p>安進公司在全球範圍內發現、開發、製造和提供人類治療藥物。公司的主要產品包括用於治療斑塊型銀屑病、類風濕性關節炎和銀屑病關節炎的恩利昔（Enbrel）；用於治療成人斑塊型銀屑病、銀屑病關節炎和與貝赫切特病相關的口腔潰瘍的奧特茲拉（Otezla）；用於治療絕經後女性骨質疏鬆症的普利亞（Prolia）；用於預防骨骼相關事件的 XGEVA；可降低心肌梗死、中風和冠狀動脈再血管化風險的 Repatha；用於治療免疫性血小板減少症患者的 Nplate；用於治療複發性或難治性多發性骨髓瘤患者的 KYPROLIS；用於治療紅細胞數量低於正常水平和貧血的 Aranesp；用於治療絕經後男性和女性骨質疏鬆症的 EVENITY；用於治療野生型 RAS 轉移性結直腸癌患者的 Vectibix；用於治療急性淋巴細胞白血病患者的 BLINCYTO；用於治療甲狀腺眼病的 TEPEZZA；以及用於治療慢性難治性痛風的 KRYSTEXXA。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過安進</li>
<li>市值計算器：如何計算市值</li>
<li>3 只中型股到大型股宣佈了重大回購</li>
<li>投資者如何找到最佳的便宜股息股票</li>
<li>這 3 只股票在過去 12 個月中為股東帶來了巨大的收益</li>
<li>如何開始投資房地產</li>
<li>知名對沖基金收購 HPE 的巨大股份：現在值得買入嗎？</li>
</ul>
<p><strong>想看看其他對沖基金持有的 AMGN 股票嗎？</strong> 請訪問 HoldingsChannel.com，獲取安進公司（NASDAQ:AMGN - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在安進嗎？</h2>
<p>在考慮安進之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而安進並不在名單上。</p>
<p>雖然安進目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

安進

<p>Capital Group Private Client Services Inc. 在第四季度減少了對安進（Amgen Inc.，NASDAQ:AMGN）27.7% 的持股，出售了 25,906 股，剩餘 67,479 股，市值為 1,759 萬美元。其他機構投資者也調整了他們的持倉，Talbot Financial LLC 增加了 5.6% 的持股。安進的股票開盤價為 277.29 美元，市值為 1,490.9 億美元，市盈率為 36.73。該公司最近宣佈每股季度股息為 2.38 美元，收益率為 3.43%</p>

<p>Capital Group Private Client Services Inc. lessened its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 27.7% in the fourth quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 67,479 shares of the medical research company's stock after selling 25,906 shares during the period. Capital Group Private Client Services Inc.'s holdings in Amgen were worth $17,588,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>資本集團私人客户服務公司在最近向證券交易委員會的披露中表示，在第四季度減少了對安進公司（NASDAQ:AMGN - 免費報告）27.7% 的持股。該基金在此期間出售了 25,906 股後，持有 67,479 股這家醫療研究公司的股票。資本集團私人客户服務公司在安進的持股在最近的報告期末價值為 17,588,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 12/2 - 12/6</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 12/2 - 12/6</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently made changes to their positions in the company. Talbot Financial LLC increased its position in shares of Amgen by 5.6% during the fourth quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock worth $11,153,000 after acquiring an additional 2,274 shares in the last quarter. Asset Advisors Investment Management LLC raised its stake in Amgen by 9.0% in the 3rd quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company's stock valued at $11,578,000 after acquiring an additional 2,954 shares during the period. Ascent Wealth Partners LLC increased its stake in shares of Amgen by 0.7% in the fourth quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after purchasing an additional 64 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Amgen by 6.0% in the 3rd quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company's stock worth $204,659,000 after buying an additional 35,785 shares during the period. Finally, ICICI Prudential Asset Management Co Ltd grew its stake in Amgen by 242.2% in the 4th quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company's stock valued at $6,255,000 after buying an additional 16,985 shares in the last quarter. Institutional investors own 76.50% of the company's stock.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也對該公司的持股進行了調整。Talbot Financial LLC 在第四季度將其在安進的持股增加了 5.6%。Talbot Financial LLC 目前持有 42,791 股這家醫療研究公司的股票，價值為 11,153,000 美元，此前在上個季度又增持了 2,274 股。資產顧問投資管理公司在第三季度將其在安進的持股提高了 9.0%。資產顧問投資管理公司目前持有 35,934 股這家醫療研究公司的股票，價值為 11,578,000 美元，此前在此期間又增持了 2,954 股。Ascent Wealth Partners LLC 在第四季度將其在安進的持股增加了 0.7%。Ascent Wealth Partners LLC 目前持有 9,024 股這家醫療研究公司的股票，價值為 2,352,000 美元，此前在上個季度又購買了 64 股。Principal Financial Group Inc.在第三季度將其在安進的持股提高了 6.0%。Principal Financial Group Inc.目前持有 635,172 股這家醫療研究公司的股票，價值為 204,659,000 美元，此前在此期間又購買了 35,785 股。最後，ICICI Prudential Asset Management Co Ltd 在第四季度將其在安進的持股增加了 242.2%。ICICI Prudential Asset Management Co Ltd 目前持有 23,999 股這家醫療研究公司的股票，價值為 6,255,000 美元，此前在上個季度又購買了 16,985 股。機構投資者持有該公司 76.50% 的股票。</p>
</div><h2>Amgen Price Performance</h2>
<div class="lb-trans"><h2>安進價格表現</h2>
</div><p>AMGN opened at $277.29 on Friday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock's 50 day simple moving average is $303.04 and its 200 day simple moving average is $294.22. The firm has a market cap of $149.09 billion, a price-to-earnings ratio of 36.73, a PEG ratio of 2.63 and a beta of 0.59. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.</p>
<div class="lb-trans"><p>安進的股票在週五開盤價為 277.29 美元。該公司的債務與股本比率為 9.62，流動比率為 1.26，速動比率為 0.95。該股票的 50 日簡單移動平均線為 303.04 美元，200 日簡單移動平均線為 294.22 美元。該公司的市值為 1490.9 億美元，市盈率為 36.73，PEG 比率為 2.63，貝塔值為 0.59。安進的 1 年最低價為 253.30 美元，1 年最高價為 346.85 美元。</p>
</div><ul>
<li>Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?</li>
</ul>
<div class="lb-trans"><ul>
<li>安進股票因減肥藥數據下跌：反應過度還是合理？</li>
</ul>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.</p>
<div class="lb-trans"><p>安進（NASDAQ:AMGN - 獲取免費報告）最近在 2 月 4 日（星期二）發佈了其財報。這家醫療研究公司報告的季度每股收益為 5.31 美元，超出市場共識預期的 5.04 美元，超出幅度為 0.27 美元。安進的淨利潤率為 12.24%，股本回報率為 176.32%。分析師預測，安進在當前年度的每股收益將達到 20.62 美元。</p>
</div><h2>Amgen Announces Dividend</h2>
<div class="lb-trans"><h2>安進宣佈分紅</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.43%. Amgen's dividend payout ratio is presently 126.09%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，將於 6 月 6 日（星期五）支付。5 月 16 日（星期五）的登記投資者將獲得每股 2.38 美元的分紅。該分紅的除息日為 5 月 16 日（星期五）。這相當於年化分紅為 9.52 美元，收益率為 3.43%。安進的分紅支付比率目前為 126.09%。</p>
</div><h2>Insider Buying and Selling at Amgen</h2>
<div class="lb-trans"><h2>安進的內部買賣</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只准備在 2025 年飆升的仿製藥股票</li>
</ul>
</div><p>In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 in the last 90 days. Insiders own 0.69% of the company's stock.</p>
<div class="lb-trans"><p>在其他安進新聞中，高級副總裁 Nancy A. Grygiel 在 2 月 5 日（星期三）出售了 1,589 股公司的股票。該股票以 304.47 美元的平均價格出售，總交易額為 483,802.83 美元。交易後，這位高級副總裁現在直接持有 7,210 股公司的股票，價值約為 2,195,228.70 美元。此次交易使其持股減少了 18.06%。該出售在向證券交易委員會提交的文件中披露，相關文件可通過 SEC 網站訪問。此外，執行副總裁 David M. Reese 在 2 月 21 日（星期五）出售了 25,225 股公司的股票。該股票以 304.44 美元的平均價格出售，總交易額為 7,679,499.00 美元。交易完成後，這位執行副總裁現在直接持有 36,922 股公司的股票，價值約為 11,240,533.68 美元。這代表其持股減少了 40.59%。該出售的披露信息可以在此找到。內部人士在過去 90 天內出售了 69,341 股公司股票，價值為 20,644,335 美元。內部人士持有公司 0.69% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>AMGN has been the subject of several recent research reports. Piper Sandler Companies reiterated an &#34;overweight&#34; rating and issued a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Citigroup reissued a &#34;neutral&#34; rating on shares of Amgen in a report on Wednesday, February 5th. Bank of America upped their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an &#34;underperform&#34; rating in a report on Wednesday, March 5th. Piper Sandler boosted their price target on shares of Amgen from $310.00 to $329.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, February 10th. Finally, Wells Fargo &amp; Company reiterated an &#34;equal weight&#34; rating on shares of Amgen in a research report on Wednesday, February 5th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $314.91.</p>
<div class="lb-trans"><p>安進最近成為幾份研究報告的主題。Piper Sandler Companies 在 1 月 2 日（星期四）的研究報告中重申了對安進股票的 “增持” 評級，並給出了 310.00 美元的目標價。花旗集團在 2 月 5 日（星期三）的報告中重申了對安進股票的 “中性” 評級。美國銀行在 3 月 5 日（星期三）將安進股票的目標價從 275.00 美元上調至 294.00 美元，並給予該股票 “跑輸大盤” 的評級。Piper Sandler 在 2 月 10 日（星期一）將安進股票的目標價從 310.00 美元上調至 329.00 美元，並給予該公司 “增持” 評級。最後，富國銀行在 2 月 5 日（星期三）的研究報告中重申了對安進股票的 “持平” 評級。兩位投資分析師對該股票給予了賣出評級，九位給予了持有評級，十二位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 314.91 美元。</p>
</div><p><strong>Check Out Our Latest Report on Amgen</strong></p>
<div class="lb-trans"><p><strong>查看我們關於安進的最新報告</strong></p>
</div><h2>About Amgen</h2>
<div class="lb-trans"><h2>關於安進</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>安進公司在全球範圍內發現、開發、製造和提供人類治療藥物。公司的主要產品包括用於治療斑塊型銀屑病、類風濕性關節炎和銀屑病關節炎的恩利昔（Enbrel）；用於治療成人斑塊型銀屑病、銀屑病關節炎和與貝赫切特病相關的口腔潰瘍的奧特茲拉（Otezla）；用於治療絕經後女性骨質疏鬆症的普利亞（Prolia）；用於預防骨骼相關事件的 XGEVA；可降低心肌梗死、中風和冠狀動脈再血管化風險的 Repatha；用於治療免疫性血小板減少症患者的 Nplate；用於治療複發性或難治性多發性骨髓瘤患者的 KYPROLIS；用於治療紅細胞數量低於正常水平和貧血的 Aranesp；用於治療絕經後男性和女性骨質疏鬆症的 EVENITY；用於治療野生型 RAS 轉移性結直腸癌患者的 Vectibix；用於治療急性淋巴細胞白血病患者的 BLINCYTO；用於治療甲狀腺眼病的 TEPEZZA；以及用於治療慢性難治性痛風的 KRYSTEXXA。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>These 3 Stocks Have Huge Last 12 Months Shareholder Yields</li>
<li>How to Start Investing in Real Estate</li>
<li>Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過安進</li>
<li>市值計算器：如何計算市值</li>
<li>3 只中型股到大型股宣佈了重大回購</li>
<li>投資者如何找到最佳的便宜股息股票</li>
<li>這 3 只股票在過去 12 個月中為股東帶來了巨大的收益</li>
<li>如何開始投資房地產</li>
<li>知名對沖基金收購 HPE 的巨大股份：現在值得買入嗎？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 AMGN 股票嗎？</strong> 請訪問 HoldingsChannel.com，獲取安進公司（NASDAQ:AMGN - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在安進嗎？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮安進之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而安進並不在名單上。</p>
</div><p>While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然安進目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Capital Group Private Client Services Inc. 出售了 25,906 股安進公司（NASDAQ:AMGN）的股票